

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 16, 2025

786-O

RRID:CVCL_1051

Type: Cell Line

Proper Citation

(RRID:CVCL_1051)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1051

Proper Citation: (RRID:CVCL_1051)

Sex: Male

Defining Citation: [PMID:721102](#), [PMID:1010528](#), [PMID:2041050](#), [PMID:6244232](#), [PMID:7915601](#), [PMID:10700174](#), [PMID:15585611](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22185343](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22949125](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30260228](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31267758](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Cell surface proteome., Omics: Array-based CGH., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: 786-O

Synonyms: 786-o, 786O, 786-0, 786.O, 786-O RCC, RCC 786-O, RCC_7860, RCC 7860, 7860, 786-0WT

Cross References: BTO:BTO_0003781, CLO:CLO_0001486, EFO:EFO_0005707, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1932, BCRC:60243, BioGRID_ORCS_Cell_line:502, BioSample:SAMN03471906, BioSample:SAMN10988199, cancercellines:CVCL_1051, CCRID:1101HUM-PUMC000243, CCRID:3101HUMSCSP5059, CCRID:3101HUMTCHu186, CCRID:4201HUM-CCTCC00159, CCRID:5301HUM-KCB09014YJ, CCTCC:GDC0159, Cell_Model_Passport:SIDM00125, ChEMBL-Cells:ChEMBL3308018, ChEMBL-Targets:ChEMBL613102, CLS:300107, Cosmic:687936, Cosmic:875874, Cosmic:897461, Cosmic:905947, Cosmic:972929, Cosmic:974305, Cosmic:982276, Cosmic:1044259, Cosmic:1092589, Cosmic:1175848, Cosmic:1305372, Cosmic:1312360, Cosmic:1481416, Cosmic:1998431, Cosmic:2036676, Cosmic:2520637, Cosmic:2663796, Cosmic-CLP:905947, DepMap:ACH-000649, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS261AAA, ENCODE:ENCBS413VCR, ENCODE:ENCBS807WMR, GDSC:905947, GEO:GSM2128, GEO:GSM50226, GEO:GSM50290, GEO:GSM482711, GEO:GSM743488, GEO:GSM750838, GEO:GSM799371, GEO:GSM799377, GEO:GSM799434, GEO:GSM843437, GEO:GSM846283, GEO:GSM886845, GEO:GSM887909, GEO:GSM1153444, GEO:GSM1177874, GEO:GSM1177875, GEO:GSM1177876, GEO:GSM1181296, GEO:GSM1181322, GEO:GSM1669572, GEO:GSM2124635, IARC_TP53:18076, IARC_TP53:28222, IZSLER:BS TCL 124, KCB:KCB 200941YJ, LiGeA:CCLE_806, LINCS_LDP:LCL-1773, Lonza:1087, MetaboLights:MTBLS737, NCI-DTP:786-0, PharmacDB:7860_28_2019, PRIDE:PXD000335, PRIDE:PXD000589, PRIDE:PXD001493, PRIDE:PXD003105, PRIDE:PXD005453, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1051, PubChem_Cell_line:CVCL_1051, SKY/M-FISH/CGH:2782, Ubigen:YC-C113, Wikidata:Q54604950

ID: CVCL_1051

Record Creation Time: 20250131T193526+0000

Record Last Update: 20250131T193601+0000

Ratings and Alerts

No rating or validation information has been found for 786-O.

No alerts have been found for 786-O.

Data and Source Information

Usage and Citation Metrics

We found 1444 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Hu X, et al. (2024) A gut-derived hormone regulates cholesterol metabolism. *Cell*, 187(7), 1685.

Liu B, et al. (2024) Radix Actinidia chinensis induces the autophagy and apoptosis in renal cell carcinoma cells. *European journal of medical research*, 29(1), 291.

Bai Y, et al. (2024) Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma. *iScience*, 27(6), 109997.

Ito J, et al. (2024) PRDX6 dictates ferroptosis sensitivity by directing cellular selenium utilization. *Molecular cell*, 84(23), 4629.

Liu Y, et al. (2024) A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN- γ Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells. *International journal of molecular sciences*, 25(7).

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Riscal R, et al. (2024) Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma. *Cancer research*, 84(10), 1570.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Li S, et al. (2024) Identify BCAT1 plays an oncogenic role and promotes EMT in KIRC via single cell RNA-seq and experiment. *Frontiers in oncology*, 14, 1446324.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. *Immunity*, 57(12), 2863.

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. *EBioMedicine*, 104, 105162.

Li F, et al. (2024) Integrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis. *Biology direct*, 19(1), 132.

Jiao M, et al. (2024) VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway. *iScience*, 27(7), 110285.

Tang G, et al. (2024) circWSB1 promotes tumor progression in ccRCC via circWSB1/miR-182-5p/WSB1 axis. *International journal of biological macromolecules*, 256(Pt 1), 128338.

Yu Y, et al. (2024) Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. *Molecular oncology*, 18(8), 1904.

Wang T, et al. (2024) SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF- β -independent manner. *Molecular oncology*, 18(1), 44.

Tran DH, et al. (2024) De novo and salvage purine synthesis pathways across tissues and tumors. *Cell*, 187(14), 3602.

Wang Y, et al. (2024) CXCL3/TGF- β -mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance. *iScience*, 27(7), 110224.

Zhou X, et al. (2023) SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer. *Cancer research*, 83(22), 3813.